Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares rose 6.8% during trading on Monday . The stock traded as high as $7.85 and last traded at $7.42. Approximately 8,747,497 shares changed hands during trading, an increase of 35% from the average daily volume of 6,502,181 shares. The stock had previously closed at $6.95.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on RXRX shares. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Jefferies Financial Group lowered their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.25.
Recursion Pharmaceuticals Trading Up 7.1 %
The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -4.85 and a beta of 0.85. The business has a 50-day moving average of $6.73 and a two-hundred day moving average of $7.25.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.43) EPS. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Insider Activity
In related news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at $4,697,960.96. The trade was a 2.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 119,235 shares of company stock worth $802,988. 15.75% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of RXRX. Axxcess Wealth Management LLC raised its position in Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after purchasing an additional 1,795 shares during the last quarter. Green Alpha Advisors LLC lifted its position in Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after buying an additional 1,800 shares in the last quarter. Interchange Capital Partners LLC grew its holdings in Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after acquiring an additional 2,349 shares during the last quarter. Amalgamated Bank raised its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after purchasing an additional 2,598 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.